Press Release
6 November 2026 07:00

Nomination Committee appointed for Bactiguard Holding AB's Annual General Meeting 2027

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 11 May 2027 in Stockholm, has been appointed. The Nomination Committee will consist of:

- Per Colleen – (appointed by TomBact AB)
- Jan Ståhlberg – (appointed by Jan Ståhlberg)
- Karsten Ferm – (appointed by Fjärde AP Fonden)
- Mats J. Andersson – (appointed by Nordea Fonder)
- Roger Storm – (appointed by Handelsbanken Fonder)

In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of five members. The Chairman of the Board of Directors shall contact the largest shareholders of the company, in terms of voting power, pursuant to Euroclear Sweden AB's print out of the share register on 31 August. Each of the largest shareholders shall be offered the opportunity to, within reasonable time, appoint a member.

The Nomination Committee will make proposals to the Annual General Meeting 2027 concerning the election of a Chairman for the Annual General Meeting, the Chairman and other members of the Board of Directors, as well as auditors. The Nomination Committee will also make proposals regarding remuneration to the Board of Directors, including any separate remuneration for committee work, as well as remuneration to the auditors. Further, the Nomination Committee will make a proposal regarding principles for forming the Nomination Committee for the Annual General Meeting in 2028.

Shareholders who wish to make proposals to the Nomination Committee can do so by writing to the Nomination Committee under the following address:

Nomination Committee Bactiguard Holding AB (publ)
P O Box 15
S - 146 21 Tullinge

Proposals can also be sent by email to the following address: valberedningen@bactiguard.com

In order for the Nomination Committee to be able to address proposals in a constructive manner, they should have been received by January 11, 2027. The proposals of the Nomination Committee will be presented in the invitation to the Annual General Meeting and on the company's website.

For further information, please contact:
Patrick Bach, CFO +46 761 295 911

About Bactiguard

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas where infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices. The company also has a portfolio of wound management products. Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard is headquartered in Stockholm and is listed on Nasdaq Stockholm and is included in the Small-Cap segment.

Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn